LAST UPDATED
March 4, 2024
Clinicaltrials.gov ID
EudraCT ID
A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19) (ZUMA-19)
The primary objectives of this study are: Phase 1: To evaluate the safety of sequenced therapy with lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B-cell lymphoma and identify the most appropriate dose of lenzilumab for Phase 2. Phase 2: To evaluate the incidence of neurologic events with sequenced therapy given at the recommended Phase 2 dose (RP2D) of lenzilumab in participants with relapsed or refractory large B-cell lymphoma.
View MoreAge
18 Years +
Sex
All
Healthy Volunteers
No
Medical Condition
Relapsed/Refractory Large B-cell Lymphoma
Gender
N/A
Date
May 2020 - March 2021
Study Type
Interventional
Study Phase
Phase 1
Product
Cyclophosphamide, Fludarabine, Lenzilumab, Axicabtagene Ciloleucel
Palo Alto, California, United States, 94305
Tampa, Florida, United States, 33612
Evanston, Illinois, United States, 60208
Rochester, Minnesota, United States, 55905
Buffalo, New York, United States, 14263
New York, New York, United States, 10032
Charlotte, North Carolina, United States, 28204
Portland, Oregon, United States, 97239
Nashville, Tennessee, United States, 37232
Houston, Texas, United States, 77030
Share Trial